<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726426</url>
  </required_header>
  <id_info>
    <org_study_id>BSMMU-001-CT</org_study_id>
    <nct_id>NCT01726426</nct_id>
  </id_info>
  <brief_title>Modulation of Anaerobic Gut Bacteria of Arsenicosis Patients by Probiotics</brief_title>
  <official_title>Modulation of Anaerobic Gut Bacteria in Palmer Arsenical Keratosis Patients by Supplementation With Probiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of anaerobic bacteria in the pathogenesis of palmer arsenical keratosis is not&#xD;
      known. This can be evaluated by administering probiotics. Thirty patients from an arsenic&#xD;
      affected area will be provided two probiotics capsules per day orally for 12 weeks and stool&#xD;
      samples will be collected for qualitative and quantitative analysis of anaerobic bacteria.&#xD;
      Similar number of arsenic exposed controls and healthy volunteers from the same area will be&#xD;
      included with similar protocol for comparison. Like aerobic bacteria, anaerobic bacteria may&#xD;
      be modulated by probiotics in arsenicosis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent study done by our laboratory shows that there are reduction in the number of E. coli&#xD;
      in the gut of patients with arsenical keratosis which is increase by the administration of&#xD;
      probiotics (manuscript is preparing). However, E.coli contribute only about 0.1% of the total&#xD;
      gut bacteria. It is not known whether anaerobic bacteria play an important role in the&#xD;
      pathogenesis of arsenical keratosis. This can be evaluated by administering probiotics.&#xD;
      Thirty patients of moderate arsenical palmer keratosis from an arsenic affected area will be&#xD;
      recruited on the basis of inclusion and exclusion criteria. They will be provided two&#xD;
      probiotics capsules per day orally for 12 weeks. Water sample will be collected before&#xD;
      starting the study for confirming the diagnosis. Stool samples will be collected twice&#xD;
      (before and after completion of the study) for qualitative and quantitative analysis of&#xD;
      anaerobic bacteria. Similar number of arsenic exposed controls (30) and healthy volunteers&#xD;
      (30) from the same area will be included in this study and they will be provided probiotics&#xD;
      capsules with similar dosage and duration. Like aerobic bacteria, anaerobic bacteria may be&#xD;
      modulated by probiotics in arsenicosis patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of pathogenic anaerobic bacteria in stool</measure>
    <time_frame>0 weeks (baseline), 12 weeks (end)</time_frame>
    <description>Number of pathogenic anaerobic bacteria in the stool of patients will be decrease in comparison to arsenic exposed controls and volunteers after 12 weeks supplementation with probiotics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arsenic level in stool</measure>
    <time_frame>0 week (baseline), 12 weeks (end)</time_frame>
    <description>Arsenic level in the stool of patients will be increased in comparison to arsenic exposed controls and healthy volunteers. Arsenic level will be estimated using Atomic Fluorescence spectrometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in palmer keratosis following supplementation</measure>
    <time_frame>0 week (baseline), 12 weeks (end)</time_frame>
    <description>There will be improvement of moderate palmer keratosis following supplementation with probiotics.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Chronic Arsenic Poisoning</condition>
  <arm_group>
    <arm_group_label>Patients of palmer arsenical keratosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arsenic exposed controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heathy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks</description>
    <arm_group_label>Arsenic exposed controls</arm_group_label>
    <arm_group_label>Heathy volunteers</arm_group_label>
    <arm_group_label>Patients of palmer arsenical keratosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Patients):&#xD;
&#xD;
          -  history of taking arsenic contaminated water (&gt;50 ppb) for more than 6 months&#xD;
&#xD;
          -  patients having moderate arsenical keratosis present on palm of the hand&#xD;
&#xD;
          -  patients those voluntarily agree to participate&#xD;
&#xD;
        Inclusion Criteria (Arsenic exposed controls):&#xD;
&#xD;
          -  family member of the patient&#xD;
&#xD;
          -  drinking arsenic contaminated water from the same source as patient&#xD;
&#xD;
          -  those voluntarily agreed to participate&#xD;
&#xD;
          -  no sign/symptoms of palmer keratosis&#xD;
&#xD;
        Inclusion Criteria (Healthy volunteers):&#xD;
&#xD;
          -  drinking arsenic safe water &lt;50 ppb)&#xD;
&#xD;
          -  those voluntarily agreed to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  lactating mother&#xD;
&#xD;
          -  patient receiving treatment of arsenicosis&#xD;
&#xD;
          -  any other chronic disease like tuberculosis, diabetes, asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University</name>
      <address>
        <city>Dhaka</city>
        <zip>1000</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 3, 2012</study_first_submitted>
  <study_first_submitted_qc>November 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2012</study_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Prof. Mir Misbahuddin</investigator_full_name>
    <investigator_title>Prof. and Chairman, Department of Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Chronic arsenic poisoning</keyword>
  <keyword>Palmer arsenical keratosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Poisoning</mesh_term>
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

